Hold an Afternoon Tea This August, drink tea, eat cake, play games, and more to help fund our research and support.
Book a Public Health Talk Raise awareness of breast cancer in your local community or network by booking a free online or in-person talk.
Home About us Media Breast Cancer Now media statements 206 results We respond to NHS England breast cancer waiting times: November 2021 13 Jan 2022 2 min read We welcome the SMC’s approval of two new treatments for use on the NHS in Scotland- trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa) in combination with trastuzumab and capecitabine 17 Jan 2022 3 min read Responding to a new AI tool being tested to establish HER2 status in breast cancer 19 Jan 2022 1 min read We respond to Professor Gilbert’s talk at UK Interdisciplinary Breast Cancer Symposium, surrounding ‘Personalised breast cancer screening’ 31 Jan 2022 1 min read We respond to House of Commons library analysis revealing record numbers of women facing delays to see an NHS cancer specialist 07 Feb 2022 1 min read Responding to new research that pembrolizumab cuts the risk of triple negative breast cancer returning by 37% 10 Feb 2022 1 min read We respond to NHS England breast cancer waiting times: December 2021 10 Feb 2022 1 min read We respond to 'The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation’ 15 Feb 2022 1 min read We respond to a new study looking at breast pain and breast cancer 22 Feb 2022 1 min read We respond to the latest COVID-19 guidance 22 Feb 2022 1 min read We respond to today's NHSE Breast Screening Programme 2020-21 report 24 Feb 2022 2 min read We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS 25 Feb 2022 2 min read Previous 1 ... 13 ... 18 Next
We welcome the SMC’s approval of two new treatments for use on the NHS in Scotland- trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa) in combination with trastuzumab and capecitabine 17 Jan 2022 3 min read
Responding to a new AI tool being tested to establish HER2 status in breast cancer 19 Jan 2022 1 min read
We respond to Professor Gilbert’s talk at UK Interdisciplinary Breast Cancer Symposium, surrounding ‘Personalised breast cancer screening’ 31 Jan 2022 1 min read
We respond to House of Commons library analysis revealing record numbers of women facing delays to see an NHS cancer specialist 07 Feb 2022 1 min read
Responding to new research that pembrolizumab cuts the risk of triple negative breast cancer returning by 37% 10 Feb 2022 1 min read
We respond to 'The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation’ 15 Feb 2022 1 min read
We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS 25 Feb 2022 2 min read
